- ScienceDaily
- 22/6/5 19:03
A scientist comments on the evolving treatment of rectal cancer in light of findings from a study that found the immunotherapy drug dostarlimab was especially effective in a phase II clinical trial of a dozen patients with a subtype of rectal cancer.